Is It Time to Leave Behind the Concept of Asthma Control and Severity Steps?
Is It Time to Leave Behind the Concept of Asthma Control and Severity Steps? J Asthma. 2019 Nov 14;:1-3 Authors: Nannini LJ Abstract After 25 years of GINA, we need an overarching strategy. The resounding changes in GINA 2019 should be accompanied by another major change in general strategy of asthma management. The concept of control asthma and step strategy was established in 1997 by GINA; but still there is a great gap between GINA objectives and outcomes. O'Byrne and colleagues proposed a continuum of care approach; where patient-adjusted therapy would comprise both a controller and reliever (usually ICS/fast-acting LABA) in a single inhaler. We use a similar approach in our asthma centre.AbbreviationsGINAglobal initiative for asthmaICSinhaled corticosteroidsLABAlong acting beta2 agonistsPRNpro re nata (as needed)SABAsShort acting beta2 agonistsESCEuropean Society of CardiologyESHEuropean Society of HypertensionGPgeneral practitionersGOALThe Gaining Optimal Asthma ControL study.FABAfast acting beta agonists.FDAfood and drug administration. PMID: 31724457 [PubMed - as supplied by publisher]
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
Purpose of Study: Explore the perceptions of primary care physicians (PCPs) from community health care centers (CHCs) in Franklin County, Ohio, regarding factors that contribute to their inability to consistently provide sustainable asthma management services to their uninsured patient population. Primary Practice Setting: Asthmatic patients are not consistently receiving sustainable asthma management in CHCs in Ohio. Primary care physicians in CHCs play a pivotal role in closing health care gaps for asthmatic patients. To minimize the barriers that impede the efforts of PCPs to control asthma for their uninsured pati...
Publication date: Available online 9 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Osamu Matsuno, Seijiro Minamoto
Publication date: Available online 8 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Francesco Menzella, Patrizia Ruggiero, Carla Galeone, Chiara Scelfo, Diego Bagnasco, Nicola Facciolongo
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Annelies L. Robijn, Daniel Barker, Peter G. Gibson, Warwick B. Giles, Vicki L. Clifton, Joerg Mattes, Michael J. Peek, Helen L. Barrett, Sean K. Seeho, Leonie K. Callaway, Alistair Abbott, John Attia, Peter A. Wark, Megan E. Jensen, Vanessa E. Murphy
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yudy K. Persaud., Jay Portnoy
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Laurits Frøssing, Alexander Silberbrandt, Anna Von Bülow, Vibeke Backer, Celeste Porsbjerg
tivitis Committee Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the world. They are frequently involved in hypersensitivity reactions, which range from local or mild reactions to systemic and severe reactions. Consequently, it is necessary to perform an exhaustive study of patients in order to make an accurate diagnosis, search for safe procedures in the case of severe reactions, and identify alternative treatment options. Various guidelines and protocols address the management of hypersensitivity to NSAIDs, although these vary widely from country to country. The Committees of A...
CONCLUSION: Treatment of SAA with omalizumab improves the outcome of associated CRSNP+, thus supporting the concept of a "one airway disease". PMID: 30931917 [PubMed - indexed for MEDLINE]